RE:Big Pharma is facing a looming $236 Billion patent cliff According to the 32nd edition of the Beyond Borders report produced by Ernst & Young LLP (EY US) contributor Arda Ural, PhD, EY Americas industry markets leader, health sciences and wellness, wrote: "...large cap biopharma industry is facing a foundational growth gap due to upcoming patent expirations for its leading blockbusters biologics and pipelines, which are not sufficient to sustain their top-line growth aspirations.
“With the pandemic boom in the rear-view mirror, flush balance sheets and a huge correction in deal target development stage biotechs, now is an opportune time for big pharma to deploy its firepower to acquire biotech innovation.”
EY US said the dealmaking value decreased by 46% when compared to last year and remains slow thus far by mid-2022. With historic drops in target valuations, big pharma players may seize the opportunity for large-scale M&A later this year, the company notes.